- Home
- ZIMV vs MIST Comparison
ZIMV vs MIST Comparison
Compare ZIMV & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIMV
- MIST
- Stock Information
- Founded
- ZIMV 2021
- MIST 2003
- Country
- ZIMV United States
- MIST Canada
- Employees
- ZIMV N/A
- MIST N/A
- Industry
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- ZIMV Health Care
- MIST Health Care
- Exchange
- ZIMV Nasdaq
- MIST Nasdaq
- Market Cap
- ZIMV 262.9M
- MIST 53.9M
- IPO Year
- ZIMV N/A
- MIST N/A
- Fundamental
- Price
- ZIMV $9.01
- MIST $1.12
- Analyst Decision
- ZIMV Hold
- MIST Strong Buy
- Analyst Count
- ZIMV 1
- MIST 2
- Target Price
- ZIMV N/A
- MIST $9.50
- AVG Volume (30 Days)
- ZIMV 109.9K
- MIST 1.6M
- Earning Date
- ZIMV 05-08-2025
- MIST 05-20-2025
- Dividend Yield
- ZIMV N/A
- MIST N/A
- EPS Growth
- ZIMV N/A
- MIST N/A
- EPS
- ZIMV N/A
- MIST N/A
- Revenue
- ZIMV $449,749,000.00
- MIST N/A
- Revenue This Year
- ZIMV $2.13
- MIST N/A
- Revenue Next Year
- ZIMV $2.44
- MIST N/A
- P/E Ratio
- ZIMV N/A
- MIST N/A
- Revenue Growth
- ZIMV N/A
- MIST N/A
- 52 Week Low
- ZIMV $8.56
- MIST $0.63
- 52 Week High
- ZIMV $22.40
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- ZIMV 40.17
- MIST 46.48
- Support Level
- ZIMV $8.61
- MIST $1.28
- Resistance Level
- ZIMV $9.27
- MIST $1.32
- Average True Range (ATR)
- ZIMV 0.40
- MIST 0.12
- MACD
- ZIMV 0.08
- MIST 0.03
- Stochastic Oscillator
- ZIMV 33.91
- MIST 38.80
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).